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We here report a genome-editing strategy to correct spinal muscular atrophy (SMA). Rather than directly
targeting the pathogenic exonic mutations, our strategy employed Cas9 and guide-sgRNA for the targeted
disruption of intronic splicing-regulatory elements. We disrupted intronic splicing silencers (ISSs, including
ISS-N1 and ISS+ 100) of survival motor neuron (SMN) 2, a key modifier gene of SMA, to enhance exon 7
inclusion and full-length SMN expression in SMA iPSCs. Survival of splicing-corrected iPSC-derived motor
neurons was rescued with SMN restoration. Furthermore, co-injection of Cas9 mRNA from Streptococcus
pyogenes (SpCas9) or Cas9 from Staphylococcus aureus (SaCas9) alongside their corresponding sgRNAs
targeting ISS-N1 into zygotes rescued 56% and 100% of severe SMA transgenic mice (Smn−/−, SMN2tg/−).
Themedian survival of the resulting mice was extended to>400 days. Collectively, our study provides
proof-of-principle for a new strategy to therapeutically intervene in SMA and other RNA-splicing-related
diseases.
Keywords: spinal muscular atrophy, SMN2, splicing-regulatory elements, CRISPR/Cas9, germline
correction
INTRODUCTION
The majority of human protein-coding genes are
able to undergo alternative pre-mRNA splicing and
pathogenic mutations that affect splicing are preva-
lent [1]. The pre-mRNA splicing process involves
multiple interactionsbetweenpre-mRNAmolecules
including cis-acting sequences present in the pre-
mRNAs that are known as splicing-regulatory ele-
ments (SREs), small nuclear ribonucleoproteins and
splicing-factor proteins [2]. Dysregulated splicing
drives the pathogenesis of multiple diseases, includ-
ing familial dysautonomia, cystic fibrosis, tau-related
disease and spinal muscular atrophy (SMA) [3–6].
SMA is the most common inherited cause of in-
fant mortality globally [7]. More than 98% of SMA
patients are homozygous for the deletion of the sur-
vival motor neuron 1 (SMN1) gene [8]. Interest-
ingly, it is known that the survival motor neuron 2
(SMN2) gene (an almost identical copy of SMN1)
is not able to fully compensate for the lack of SMN1
(and its functional gene product: full-length sur-
vival motor neuron (SMN) protein (SMN-FL)) in
SMA patients; this is because, compared to SMN1,
SMN2 has a translationally silent C-to-T transition
at position 6 in its seventh exon that, via alterna-
tive splicing, causesmore than 90% of the SMNpro-
tein produced by cells to be truncated and thus non-
functional [9,10]. Specifically, this C-to-T transition
changes an exonic splicing enhancer into an exonic
splicing silencer by destroying a binding site for the
pre-mRNA-splicing factor SF2/ASF (aka SRSF1)
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and simultaneously creating a binding site for the
nuclear ribonucleoprotein hnRNPA1 that functions
in pre-mRNA processing [11,12]. It is well estab-
lished that both hnRNPA1 and hnRNPA2 can bind
to two SREs located in intron 7 of SMN2: ISS (in-
tronic splicing silencer)-N1 and ISS+ 100 [13–15].
This binding, which helps in the fine-tuning of the
repression of exon 7 splicing, has pathomechanistic
consequences in SMA [16].
The CRISPR/Cas9 RNA-guided genome engi-
neering system, a Type II CRISPR-Cas bacterial
adaptive immune system, has great potential for
correcting disease-causingmutations [17–19]. Cas9
from Streptococcus pyogenes (SpCas9) or Staphylo-
coccus aureus (SaCas9) can be directed by single-
guide RNAs (sgRNAs) to specific genomic loci,
where they induce double-strand breaks (DSBs)
adjacent to so-called protospacer-adjacent motifs
(PAMs) (NGG for SpCas9 and NNGRRT for
SaCas9). DSBs are then resolved by either the non-
homologous end-joining (NHEJ) repair pathway
or the homology-directed repair (HDR) pathway:
NHEJ introduces additional insertions or deletions
(indels) at the DSBs; HDR can ‘correct’ a mutant
allele by replacing the original sequence with a sup-
plied exogenous DNA molecule [20]. It is widely
accepted that NHEJ-based genome editing is more
convenient and efficient than HDR-based methods
[21,22].
Here, we report our successful development of
a genome-editing strategy for the Cas9-mediated
disruption of SREs as an alternative to adopting
the typical genome-editing approach of targeting
pathogenic exonic mutations. Our results showed
that CRISPR/Cas9-based disruption of two SMN2
SREs (ISS-N1 and ISS + 100) rescued the SMA
phenotypes in human inducedpluripotent stemcells
(iPSCs) and in germline-corrected SMA mice. We
remarkably enhanced SMN2 exon 7 inclusion rates
and increased SMN-FL expression in SMA patient-
derived iPSCs and motor neurons (MNs). Further-
more, 62.8% of the severe SMA mice (Smn−/−,
SMN2tg/−) could be rescued by zygote co-injection
of SpCas9 or SaCas9 mRNA and their correspond-
ing sgRNAs targeting ISS-N1. The median lifespan
of the germline-corrected SMA mice markedly in-
creased to >400 days, with a maximum lifespan of
>600 days.
RESULTS
Alternative splicing is corrected in SMA
iPSCs with SMN2-ISSs disruption
Our strategy for disrupting theSMN2-ISSs inhuman
SMA iPSCs was based on three sgRNAs (sgRNA1,
2 and 3) that we designed to target ISS-N1 and
one sgRNA (sgRNA4) to target ISS+ 100 (Fig. 1A
and Supplementary Fig. 1A). We generated iPSCs
from fibroblasts of a wild-type (WT) control and an
SMA patient with 2 SMN2 copies (termed SMA-1)
using a non-integrating Sendai virus. We obtained
an additional SMA iPSC line with three SMN2
copies (termed SMA-2) from Coriell Cell Reposi-
tories (Supplementary Fig. 1B). All iPSCs displayed
human embryonic stem-cell (hESC) morphology,
expressed characteristic pluripotency markers (AP,
NANOG, OCT4, SOX2, TRA-1–60 and SSEA-4)
(Supplementary Fig. 2A), exhibited normal kary-
otypes (Supplementary Fig. 2B) and generated ter-
atomas in vivo (Supplementary Fig. 2C).
Plasmids expressing Cas9 and each of the four
sgRNAs were separately transfected into SMA-2 to
test the cutting efficiency of each sgRNA. A T7 en-
donuclease I (T7EI) assay,which specifically cleaves
heteroduplexes formed by the hybridization of WT
and mutant DNA sequences, revealed that sgRNA1
and sgRNA4 target ISSs, with 5.28% and 2.14% effi-
ciency, respectively. In contrast, no DSBs were de-
tected with sgRNA2 or sgRNA3 (Supplementary
Fig. 3A), so we used sgRNA1 targeting ISS-N1 and
SpCas9 vectors for transfection of SMA-2 iPSCs
followed by an enhanced green fluorescence selec-
tion protocol. Screening of 54 clones revealed that
13 (24.1%) of the splicing-corrected SMA-2 clones
showed NHEJ, of which 9 (69.2%) showed the de-
sired splicing correction (Fig. 1B). To test the ef-
ficiency of sgRNA4 in disrupting ISS + 100, we
further transfected SMA-2 iPSCs with a plasmid
that contained both Cas9 and sgRNA4, and found
that 45% (5/11) of clones showed NHEJ, of which
60% (3/5) showed the desired splicing correction
(Fig. 1B).
Subsequently, we used sequencing and reverse-
transcription polymerase chain reaction (RT-PCR)
to examine associations between particular clonal
genotypes and the extent of full-length SMN2
(SMN2-FL) mRNA expression. The SMN2-FL
mRNA expression level was strongly promoted
among the splicing-corrected iPSCs (termed SC-
SMA) (Fig. 1C and D). Moreover, RT-PCR anal-
ysis revealed that only one of the three SMN loci
harbored an edited ISS-N1 or ISS + 100, which
was sufficient to correct splicing (Fig. 1C and D).
Immunoblotting results also confirmed that SMN
protein expression was significantly increased in
splicing-corrected clones (Supplementary Fig. 3B
and C). We also confirmed the splicing correction
of Cas9-mediated SREs disruption in SMA-1 iPSCs
(Supplementary Fig. 3D–F).
We next treated unedited SMA-2 iPSCs with
an antisense morpholino oligonucleotide (MO-10–
29) [23] targeting ISS-N1, which increased the
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Figure 1. Alternative splicing is modulated in ISS-N1 and ISS+ 100 disrupted SMA iPSCs and motor neurons. (A) Schematic
of CRISPR/Cas9-mediated disruption of ISS-N1 and ISS+ 100 in intron 7 of SMN2. (B) NHEJ and splicing-modulation efficien-
cies by targeting ISS-N1 and ISS+ 100. (C) Alignments of corrected sequences from SMA iPSCs with Cas9-sgRNA-mediated
disruption at the ISS-N1 and ISS+ 100 loci. The deletions are indicated by a red dashed line. Blue lines indicate the two core
motif sequences (CAG and AAAG) of ISS-N1. The column on the right indicates the percent of the relevant genotype in total
sequencing reads. (D) RT-PCR analysis of SMN2 mRNA in SMA patient-derived iPSCs. The SC-SMA iPSCs were evaluated
at passages (p) 10 and 30. Incl% = (FL/(FL + 7)) × 100. (E) RT-PCR analysis of SMN2 mRNA in iPSCs. The ASO-treated
SMA-2 iPSCs were assessed at p1(Day (D) 1), p1(D5), p2 and p5. (F) Nuclear Gemini body localization in motor neurons
co-stained with SMN and HB9 antibodies. Gemini bodies are indicated by arrows. Scale bar, 10 μm. (G) Quantification of
SMN+ Gemini bodies in HB9+ MNs at Day 13; n = 3, with about 100 cells examined per group. (H) MNs were treated
with DMSO or 40 μM tunicamycin for 38 h. HB9 was used to mark surviving MNs, counterstained with DAPI. Scale bar,
100 μm. (I) Quantification (ratio of surviving MNs to total cells) of cell viability after tunicamycin treatment; cell viability
was increased in SC-SMA-iPSCs-derived MNs; n = 3. (J) Treated MNs were assayed with TUNEL to mark apoptotic cells.
Scale bar, 100 μm. (K) Quantification of dead MNs to total cells after tunicamycin treatment. The extent of MN apopto-
sis was reduced in SC-SMA-iPSCs-derived MNs; n = 3. Error bars indicate means ± SDs. ns, not significant; ∗P < 0.05;
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decreased to the level of untreated cells with contin-
ual passaging (Fig. 1E). This compares to the per-
manent effects of disrupting an SRE by our strategy.
Moreover, our genome-edited iPSCs retained uni-
form expression of pluripotency markers (Supple-
mentary Fig. 4A), karyotype stability (Supplemen-
tary Fig. 4B) and the ability to generate teratomas in
vivo (Supplementary Fig. 4C). We used Digenome-
seq (in vitro Cas9-digested whole-genome sequenc-
ing) to further measure the genome-wide Cas9 off-
target activity of our sgRNAs in SMA iPSCs [24,25].
A total of 29 potential off-target sites (1 for sgRNA1
and 28 for sgRNA4) throughout the genomes of
multiple iPSCs clones were captured in an un-
biased manner using Digenome-seq and none of
the potential regions sequenced showed off-target
cleavage (Supplementary Table 1). To further con-
firm the specificity of these sgRNAs on a genome-
wide scale, we also performed high-throughput
mRNA sequencing on the splicing-corrected iP-
SCs (SC-SMA-2-2 and SC-SMA-2-3) generated us-
ing sgRNA1 or sgRNA4. Neither of the two iPSCs
showeddetectable off-target effects (Supplementary
Fig. 5), highlighting that sgRNA1- and sgRNA4-
guided gene targeting and splicing regulation are ap-
parently highly specific editing processes.
SMN restoration relieves the
degeneration of SMA iPSCs-derived MNs
We then used a modified version of a previously
described cell-culture protocol to differentiate the
splicing-corrected iPSCs lines into MNs [26,27].
We successfully differentiated one WT iPSCs, two
SMA iPSCs (SMA-1 and SMA-2) and three estab-
lished isogenic SC-SMA-2 iPSCs into spinal MNs
(Supplementary Fig. 6). Unlike the unedited con-
trol MNs, the MNs derived from splicing-corrected
SMA iPSCs had many Gemini bodies—nuclear ag-
gregate structures formed by SMN (Fig. 1F and
G). These findings suggest that the disruption of
SMN2-ISSs can restore SMN expression in SC-
SMA-iPSCs-derivedMNs.
The SMN protein has minimal anti-apoptotic
effects and SMN depletion activates a high basal
level of endoplasmic reticulum (ER) stress signal-
ing to cause apoptosis in MNs [28]. To investigate
whether the increased SMN protein levels resulting
from our editing strategy reduce MN sensitivity to
exogenous ER stress, we treated all of our iPSCs-
derived MNs for 38 h with 40 μM tunicamycin—
a compound that induces ER stress [29]. We ob-
served that SMA MNs were more vulnerable to tu-
nicamycin treatment (∼75% MNs loss, P < 0.001)
than WT cultures (∼35% MNs loss) and than
SC-SMA-2 cultures (∼42%MNs loss) (Fig. 1H and
I). However, there were no significant differences
among dimethyl sulfoxide (DMSO)-treated control
cultures (P> 0.1, Fig. 1H and I). Next, we assessed
the extentof apoptosis using aTUNELassay after tu-
nicamycin treatment. Increased apoptosis was seen
in SMA MN cultures as compared with WT and
SC-SMA-2 cultures (P< 0.001), with about 78% of
SMA, 33% of WT and 43% of SC-SMA-2 cultures
stained positively for TUNEL (Fig. 1J andK).Over-
all, these results establish that increasing SMN levels
can ameliorate the degeneration of SMAMNs.
CRISPR/Cas9-mediated disruption of
SMN2 ISS-N1 in mice germline DNA
prevents SMA
Having thus established that our strategy worked
as designed and successfully rescued disease symp-
toms in both iPSCs and MNs, we next investigated
whether an SMA disease model mouse (Smn−/−;
SMN2tg/−) [30] could be rescued by the disruption
of the SMN2-ISSs. SpCas9 mRNA and sgRNA1 tar-
geting ISS-N1, the most common target for treat-
ing SMA [31], were co-injected into the cytoplasm
of zygotes (harvested from heterozygous BH mice
(Smn+/−) that had been previously mated with
type III HF mice (Smn−/−; SMN2tg/tg)) (Fig. 2A).
Furthermore, sgRNA1 targeting caused no obvi-
ous deleterious effect on the birth rate of ISS-N1-
disrupted mice compared with control non-ISS-N1
sgRNA targeted mice (injected with non-ISS-N1
sgRNA in our laboratory) (Supplementary Fig. 7A).
Of the 36 live SMA pups born, 20 hadNHEJ edits at
the SMN2 ISS-N1 locus and 85% (17/20) of these
were rescued for SMA disease symptoms and had
lifespans that reached >100 days (Fig. 2B). More-
over, the splicing-corrected SMA (SC-Sp-SMA)
mice showed a significant improvement in median
lifespan to >400 days (SC-Sp-SMA-5∼14#); this
was only 13 days for unedited control SMA mice
(Fig. 2C and Supplementary Table 2). So far, 58.3%
of the SC-Sp-SMA mice remain alive and the max-
imum survival time has reached 600 days. Of note,
the body weight of SC-Sp-SMA mice was elevated
(Fig. 2D). At postnatal Day (P) 9,most SC-Sp-SMA
micewere comparable in size to their littermate con-
trol mice (Fig. 2E).
We performed righting-reflex and grip-strength
tests to further assess the motor function of SC-
Sp-SMA mice. Compared with non-corrected SMA
mice, SC-Sp-SMA mice were faster in righting up
at P11 (Supplementary Fig. 7B). To evaluate the
muscle strength of SC-Sp-SMAmice, forelimb grip-
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Figure 2. Disruption of ISS-N1 alleviated SMA-associated phenotypes in splicing-corrected SMA mice. (A) Strategy of the
CRISPR/Cas9-mediated disruption of ISS-N1 in SMA mice via germline gene therapy. (B) NHEJ and survival efficiencies
in SC-SMA mice. (C) Kaplan–Meier survival curves for SC-Sp-SMA mice edited by SpCas9-sgRNA (n = 10), SMA mice
(n= 35), heterozygous (HET) mice (n= 10) and SC-HET mice (n= 10). (D) Body weight was assessed from P6 to P48 for SMA
(n = 15), SC-Sp-SMA (n = 20), HET (n = 8) and SC-HET (n = 19) mice. (E) Two SC-Sp-SMA mice were similarly sized with
their heterozygous littermates. (F) RT-PCR analysis of SMN2 mRNA in multiple tissues from SMA and SC-Sp-SMA mice. (G)
Immunoblot analysis of SMN protein in spinal-cord and brain samples from SMA and SC-Sp-SMA mice. (H) Kaplan–Meier
survival curves for SC-Sa-SMA mice disrupted by SaCas9-sgRNA (n = 7) and SC-HET mice (n = 12). Data from SMA mice
were the same as in (C). (I) Body weight was assessed from P5 to P59 for SC-Sa-SMA (n = 7) and SC-HET (n = 12) mice.
Data from SMA mice were the same as in (D). (J) RT-PCR analysis of SMN2 mRNA in multiple tissues from SMA and SC-Sa-
SMA mice. (K) Editing efficiency in different organs of the edited mice (lifespan >400 days). Wild-type (WT) reads without
mutations are represented by orange bars; mutant reads of ISS-N1 are represented by blue bars. Mut, mutant. Error bars
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Because of their short lifespan (∼13 days), the
non-corrected SMA mice were unsuitable for inclu-
sion in this experiment. We therefore compared our
SC-Sp-SMAmicewith heterozygous littermatemice
(Smn+/−; SMN2tg/−, termed SC-HET mice) and
observedno significant differences in strength atP33
(Supplementary Fig. 7C).
We next examined SMN expression in six dif-
ferent organs of SC-Sp-SMA mice at P9. RT-PCR
analysis showed that, compared to SMA mice, all
of the tested organs of the SC-Sp-SMA mice had
increases in their exon 7 inclusion rates (∼50%
vs ∼7%) (Fig. 2F) and immunoblotting confirmed
the increased accumulation of the SMN protein
(Fig. 2G). Note that we did observe considerable
variation in the SMN levels among the four SC-Sp-
SMA mice that we examined; genotyping analysis
revealed that this variation could be explained by
differences in the sequences produced by NHEJ
editing in the different progeny (Supplementary
Fig. 7D and Supplementary Table 2), with the high-
est levels of SMN resulting from edits to initial CAG
or AAAGmotifs.
In addition to the SC-Sp-SMA mice, we also
generated splicing-corrected mice by co-injecting
SaCas9 mRNA and sgRNA5 into zygotes. This pro-
duced seven live SC-Sa-SMA pups that all had dis-
ruption of SMN2 ISS-N1 and that had significant in-
creases in their median survival times (>400 days,
SC-Sa-SMA-3∼9#) and body weights (Fig. 2H and
I, and Supplementary Table 3). We did observe
variation in the lifespan of SC-Sa-SMA mice; geno-
typing analysis revealed that this variation could
be explained by differences in the sequences pro-
duced by NHEJ editing (Supplementary Fig. 7D
and Supplementary Table 3) and mice with the
CAG or AAAG motif edited exhibited the longest
lifespan. RT-PCR analysis indicated that alternative
splicing of SMN2 mRNA was corrected in these
pups. Compared to SMA mice at P9, the SC-Sa-
SMA mice exhibited increases in the exon 7 in-
clusion rate in multiple tissues (∼95% vs ∼7%)
(Fig. 2J).
It iswidely appreciated that germline-editedmice
frequently exhibit mosaicism [32,33]. We there-
fore conducted an experiment in which we sam-
pled six different organs from three SC-Sp-SMA
mice and two SC-Sa-SMA mice (all their lifespans
>400 days) to quantify WT and mutant allele in-
del frequencies in different lines: deep-sequencing
analysis showed variable distributions of post-edit
genotypes. The correction rates for SMN2 in differ-
ent organs from genetically mosaic SC-SMA mice
ranged widely, from 18% to 90% (Fig. 2K). We
used Digenome-seq to examine off-target effects in
the SMA mice genome and observed no potential
off-target mutations for sgRNA1 and only one for
sgRNA5; we further examined this putative off-
target mutation in the spinal cord and muscle of
SC-SMA mice using deep sequencing and no such
mutations were found in genomic DNA from these
tissues (Supplementary Table 4). These results in-
dicate that our strategy of disrupting ISS-N1 is
an effective method for rescuing SMA phenotypes
in mice.
We subsequently performed immunohistochem-
ical analysis of Gemini body number, MN counts
and neuromuscular-junction (NMJ) innervation
patterns in SC-Sp-SMA mice. A striking elevation
in the proportion of cells containing Gemini bodies
was observed in SC-Sp-SMA mice compared with
untreatedSMAmice (Fig. 3A–C).Moreover, the ex-
tent of the spinalMNdegeneration andNMJ dener-
vationwas significantly reduced inSC-Sp-SMAmice
as compared to untreated SMAmice (Fig. 3D–F and
Supplementary Fig. 7E).
SMN function was restored and inherited in the
progeny of rescued SMAmice.
We next assessed reproductive ability after dis-
ruption of ISS-N1.The founder SC-Sp-SMA female
mice were crossbred to heterozygous BH (Smn+/−)
male mice. These crosses generated nine homozy-
gous F1 SC-Sp-SMA mice and one unedited SMA
mouse (Supplementary Fig. 7F and G). All of the
F1 SC-Sp-SMA pups had normal lifespans and body
weights (Fig. 3G and Supplementary Fig. 7G). RT-
PCR and immunohistochemistry analyses showed
that the F1 SC-Sp-SMA pups had stronger SMN
expression than the SMA mice (Fig. 3H and Sup-
plementary Fig. 7H) and had significantly increased
numbers of MNs and properly innervated NMJs
(Supplementary Fig. 7I and J).Thus, SMN function
was effectively restored and inherited in the progeny
of SC-Sp-SMAmice.
DISCUSSION
We induced Cas9-mediated SREs disruption in
SMA patient-derived iPSCs and in mouse zygotes
with high efficiency. In vitro, SMN2 splicing correc-
tion and SMN-FL restoration were seen once one
copy of theCAGorAAAGmotif had been disrupted
in SMN2-ISSs of SMA iPSCs. Notably, MNs differ-
entiated from SC-Sp-SMA iPSCs exhibited signif-
icantly reduced apoptosis. In vivo, SMA mice res-
cued by germline SMN2-ISSs disruption exhibited
enhanced lifespan, bodyweight andmotor function-
ing, as well as significantly increased numbers of
MNs and properly innervated NMJs.
Several aspects of this new strategy merit
consideration. First, by targeting an intronic splic-
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Figure 3. SMN restoration alleviates spinal MN degeneration and NMJ denervation in SC-Sp-SMAmice. (A) Nuclear Gemini
bodies localization in spinal-cord L1–L2 motor neurons was determined by co-staining with SMN and ChAT antibodies. Nuclei
were counterstained with DAPI. Gemini bodies are indicated by arrows. Scale bar, 50μm. (B) and (C) Quantification of Gemini
bodies per 100 motor neurons (B) and percentage of motor neurons containing zero, one, two, three, four or more Gemini
bodies (C) in SMA (n = 3), SC-Sp-SMA (n = 6) and SC-HET (n = 3) mice. (D) Representative images of spinal-cord L1–L2
ventral-horn ChAT+ MNs (red) in the above three groups. Scale bar, 100 μm. (E) MNs labeled in (D) were counted. SMA
(n = 6), SC-Sp-SMA (n = 5) and SC-HET (n = 6). (F) Quantification of the innervated NMJs in SMA (n = 3), SC-Sp-SMA
(n= 5) and SC-HET (n= 4) mice. (G) Body weight was assessed from P5 to P59 for F1-SC-Sp-SMA (n= 9). Data from SMA
mice and SC-HET were the same as in Figure 2 (I). (H) Statistical analysis of SMN2 mRNA in multiple tissues from SMA and
F1-SC-Sp-SMA mice. Error bars indicate means ± SDs. ns, not significant; ∗P< 0.05; ∗∗P< 0.01; ∗∗∗∗P< 0.0001; one-way
ANOVA.
approach dramatically reduces the likelihood of
inducing pathogenic frameshift mutations in the
protein-coding sequence of the targeted gene.
Second, considering the widely appreciated fact that
NHEJ-mediated disruption of SREs ismore efficient
than HDR-mediated mutation replacements, it is
reasonable to anticipate that the disruption edits
needed in our approach are easier to generate than
precise in-frame exonic edits. It is also notable that
no exogenous DNA template is needed with our
SREs disruption strategy. With future discoveries
and engineering of additional Cas9 species or other
endonucleases that generate DSBs, it is likely that
potentially every SRE can be precisely targeted
for disruption [34–37]. Importantly, although
our current analysis focused only on two SREs of
the SMN2 gene, similar approaches are should be
applicable for other SREs, thereby substantially
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Antisense oligonucleotide(s) (ASO) hold
promise for the treatment of multiple neurodegen-
erative diseases. Nusinersen (SpinrazaTM), an ASO
masking ISS-N1, is the first approved SMA thera-
peutic for pediatric and adult patients [38]. Despite
its long half-life in the central nervous system
(CNS), it requires four loading doses, followed by
three annual maintenance doses, subjecting patients
to repeated intrathecal injections [39]. Importantly,
as NHEJ-mediated disruption of SREs induces a
permanent splicing correction, our strategy obviates
the need for continual administration of ASOs.
The recently US Food and Drug Administration-
approved adeno-associated virus (AAV) serotype
9 (AAV9) carrying SMN complementary DNA
encoding the missing SMN protein, AVXS-101
(Zolgensma R©), is a single-dose gene-replacement
therapy for SMA. As such single-dose correction is
not always effective and it is unmanageable to keep
injecting the virus, treatment with Spinraza remains
as an option to treat those failures [40,41].
SaCas9 has been shown tomediate genome edit-
ing in vivo with high efficiency and specificity [42].
We also found that SaCas9-mediated SMN2-ISSs
editing was especially successful, achieving a high-
yield generation of embryos carrying the ablated
ISS-N1 sequences.We did observe variation in lifes-
pan of germline-corrected SMA mice using SpCas9
and SaCas9, which could be explained by differ-
ences in the sequences produced by NHEJ edit-
ing. To achieve more efficient and specific disrup-
tion, the advent of advanced gene-editing tools (e.g.
the most recently developed sgRNA indel predic-
tion model—inDelphi) could assist in selecting su-
perior sgRNAs in the future [43]. Any hypothetical
targeting of human embryos for editing would re-
quire knowledge about which genotypes from each
of the parents would suggest an increased prob-
ability of producing offspring with a homozygous
SMN1mutation; however, medical ethics standards
prevent human germline editing [44].
Considering variable efficiencies of germline
editing on mouse pups, the limited availability of
zygotes in humans imposes a major technical chal-
lenge in therapeutic applications, besides ethical
problems. Previous studies have also revealed the
contribution of both cell-autonomous and cell-non-
autonomous SMA pathogenesis [45,46]. More-
over, systemic administration (e.g. subcutaneous
or intraperitoneal injection) of ASO appears to
be more effective than intrathecal or intracerebral
ventricular injection [31,47], suggesting unclear
SMN restored cell type(s) that directly contributes
to the observed benefit. Considering postnatal cor-
rection by CRISPR/Cas9-mediated gene editing, it
is also important to determine the efficacy of vari-
ous delivery options (e.g. AAV, lipid nanoparticle,
exosomes) [48,49].
In summary, we have achieved efficient and
safe Cas9-mediated SMN2-ISSs disruption in SMA
iPSCs and mice; this disruption corrects SMN2
splicing errors and restores functional SMN.Despite
inconclusive findings regarding the feasibility of our
approach in humans, our study establishes a proof-
of-principle demonstration for SMA rescue using a
strategy based on CRISPR/Cas9-mediated disrup-
tion of SREs and thus opens the door for the further
development of efficient interventions to treat aber-
rant splicing diseases such as familial dysautonomia,
cystic fibrosis and tau-related disease.
METHODS
Thedetailed descriptions ofmethods are available as
Supplementary Materials atNSR online.
SUPPLEMENTARY DATA
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